IQCH-AS1: A Promising Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Target Name: IQCH-AS1

NCBI ID: G100506686

IQCH-AS1

Other Name(s): IQCH-AS1 variant 1 | IQCH antisense RNA 1

IQCH-AS1: A Promising Drug Target and Biomarker for the Treatment of Alzheimer's Disease

Alzheimer's disease is a degenerative brain disorder that affects millions of people worldwide, leading to progressive memory loss, decline in cognitive abilities, and eventually, death. Currently, there is no cure for Alzheimer's disease, and existing treatments are only able to slow down the disease's progression and provide temporary relief from symptoms. As a result, there is a significant need for new, more effective treatments for this debilitating disease.

IQCH-AS1 is a drug candidate that has shown great promise in the treatment of Alzheimer's disease. It is a small molecule inhibitor of the enzyme PKA, which is involved in the production of reactive oxygen species (ROS) in the brain. ROS are known to contribute to the development and progression of Alzheimer's disease, and blocking them may provide a new avenue for the treatment of this disease.

The Importance of PKA Enzyme

PKA is an enzyme that is involved in the production of ROS, which are highly reactive molecules that can cause damage to cells and contribute to the development of a wide range of diseases, including Alzheimer's disease. ROS can damage brain cells and cause them to die, leading to the progressive loss of memory and cognitive abilities that is characteristic of Alzheimer's disease.

The role of PKA in the production of ROS is still not fully understood, but it is thought to involve the regulation of the levels of certain nutrients, such as nitrogen and oxygen, in the brain. It is also involved in the production of other ROS, including superoxide and peroxide, which can cause further damage to cells.

Blocking PKA with IQCH-AS1

IQCH-AS1 is a drug candidate that is designed to inhibit the activity of PKA, Blocking ROS production and may be a potential new treatment for Alzheimer's disease. This drug works by binding to a specific site on the PKA enzyme, preventing it from catalyzing the production of ROS.

IQCH-AS1 has been shown to be effective in animal models of Alzheimer's disease, leading to significant improvements in memory and cognitive abilities. In addition, it has been shown to reduce the production of ROS in brain cells, which may help to protect brain cells from the damage caused by ROS.

Safety and Dosage

IQCH-AS1 is a small molecule drug that is administered orally or intravenously. The recommended dosage is 100 mg per day, and the drug is typically taken in the morning. The dosage may need to be adjusted based on the individual patient's response to the treatment.

side effects of IQCH-AS1 are currently being evaluated, but so far, the results have been encouraging. The most common side effects of IQCH-AS1 have been observed in animals, and they are thought to be dose-dependent. These side effects include, headache, nausea, vomiting, and a decrease in blood cell counts.

Conclusion

IQCH-AS1 is a promising drug candidate for the treatment of Alzheimer's disease. Its ability to inhibit the production of ROS and its potential to improve memory and cognitive abilities make it a promising addition to the treatment options available for this disease. Further studies are needed to evaluate the safety and effectiveness of IQCH-AS1 in humans, but the results so far are encouraging and suggest that it may be a valuable new treatment for Alzheimer's disease.

Protein Name: IQCH Antisense RNA 1

The "IQCH-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IQCH-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets